OTCMKTS:ALIOF - Actelion Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$278.50
Today's Range$278.50 - $278.50
52-Week Range$138.01 - $286.30
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.

Receive ALIOF News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIOF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals



Sales & Book Value

Annual Sales$2.46 billion



Next Earnings DateN/A
OptionableNot Optionable

Actelion (OTCMKTS:ALIOF) Frequently Asked Questions

What is Actelion's stock symbol?

Actelion trades on the OTCMKTS under the ticker symbol "ALIOF."

How were Actelion's earnings last quarter?

Actelion Ltd (OTCMKTS:ALIOF) posted its earnings results on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $1.09 by $0.22. The company earned $501.50 million during the quarter, compared to analysts' expectations of $546.30 million. View Actelion's Earnings History.

Has Actelion been receiving favorable news coverage?

News articles about ALIOF stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Actelion earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Actelion's key competitors?

What other stocks do shareholders of Actelion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actelion investors own include Kamada (KMDA), Shire (SHPG), Neurotrope (NTRP), Voyager Therapeutics (VYGR), Align Technology (ALGN), BioMarin Pharmaceutical (BMRN), GALAPAGOS NV/S (GLPG), Illumina (ILMN), Johnson & Johnson (JNJ) and Genmab A/S (GNMSF).

Who are Actelion's key executives?

Actelion's management team includes the folowing people:
  • Jean-Pierre Garnier Ph.D., Chairman of the Board of Directors (Age 69)
  • Jean-Paul Clozel, Chief Executive Officer, Member of the Executive Committee, Delegate of the Board of Directors (Age 62)
  • Thomas Widman, Co-Founder
  • Andre C. Muller, Chief Financial Officer, Executive Vice President, Member of the Executive Committee (Age 53)
  • Otto Schwarz, Chief Operating Officer, Executive Vice President, Member of the Executive Committee (Age 61)
  • Guy Braunstein, Executive Vice President, Head of Global Clinical Development, Member of the Executive Committee (Age 60)
  • Nicholas Franco, Executive Vice President, Chief Business Development Officer, Member of the Executive Committee (Age 54)
  • Martine Clozel, Senior Vice President, Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Actelion Executive Committee (Age 61)
  • Marian Borovsky, Senior Vice President, Group General Counsel, Member of the Extended Actelion Executive Committee, Corporate Secretary to the Board of Directors (Age 47)
  • Christian Albrich, Senior Vice President, Head Global Human Resources, Member of the Extended Actelion Executive Committee (Age 52)

How do I buy shares of Actelion?

Shares of ALIOF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Actelion?

Actelion has a market capitalization of $0.00 and generates $2.46 billion in revenue each year.

What is Actelion's official website?

The official website for Actelion is http://www.actelion.com/.

How can I contact Actelion?

Actelion's mailing address is Gewerbestrasse 16, Allschwil V8, 4123. The company can be reached via phone at 41-61-565-6565 or via email at [email protected]

MarketBeat Community Rating for Actelion (OTCMKTS ALIOF)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about Actelion and other stocks. Vote "Outperform" if you believe ALIOF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIOF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by MarketBeat.com Staff

Featured Article: Options Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel